Drugs / SGC001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07091929 | Jan → Jul 2025 | myocardial infarction | Beijing Sungen Biomedical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07079618 | Aug 2024 → Jul 2025 | myocardial infarction | Beijing Sungen Biomedical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07306182 | Mar 2026 → Apr 2027 expected | ST-elevation myocardial infarction | Beijing Sungen Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGC001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07306182 ↗ |
| Route | Intravenous | “single intravenous injection completed within 6 hours of disease onset.” NCT07079618 ↗ |